Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 4.53 is 14% above its 5-year average of 3.96, around the middle of its 5-year range (3.22–5.10).
22.60% above its 12-month average of 3.70.
Reported annual fiscal-period values; no daily interpolation.
PS RATIO
4.53
PS RATIO AVG TTM
3.70
PS RATIO AVG 3Y
3.53
PS RATIO AVG 5Y
3.96
PS RATIO AVG 10Y
3.97
PS RATIO AVG 15Y
3.86
PS RATIO AVG 20Y
3.84
CURRENT VS TTM AVG
+22.60%
CURRENT VS 3Y AVG
+28.24%
CURRENT VS 5Y AVG
+14.30%
CURRENT VS 10Y AVG
+14.00%
CURRENT VS 15Y AVG
+17.43%
CURRENT VS 20Y AVG
+18.06%
SECTOR MEDIAN · HEALTHCARE
3.46
median of 85 covered companies
CURRENT VS SECTOR MEDIAN
+30.92%
vs the sector median at left
Market Cap
$358.76B
PS Ratio
0.80
TTM Avg
0.72
3Y Avg
1.04
5Y Avg
1.24
Market Cap
$234.38B
PS Ratio
5.05
TTM Avg
4.51
3Y Avg
4.65
5Y Avg
4.92
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 4.53 | 3.70 | 3.53 | 3.96 |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 0.80 | 0.72 | 1.04 | 1.24 |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 5.70 | 4.21 | 4.31 | 4.36 |
| AbbVie Inc. (ABBV)vs › | $455.87B | 7.23 | 6.60 | 5.95 | 5.36 |
| AstraZeneca PLC (AZN)vs › | $255.15B | 4.23 | 4.77 | 4.57 | 4.68 |
| Amgen Inc. (AMGN)vs › | $235.85B | 6.28 | 5.08 | 5.17 | 5.11 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 5.05 | 4.51 | 4.65 | 4.92 |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 4.10 | 4.47 | 9.86 | 10.62 |
| Abbott Laboratories (ABT)vs › | $193.04B | 4.27 | 4.42 | 4.75 | 4.71 |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 6.04 | 5.54 | 4.45 | 4.00 |
At 4.53, P/S is above its 27-year median — higher than 79% of readings in its 27-year history.
27-year low
1.63
median
3.54
27-year high
5.16
P/S Ratio
4.53
Market Cap / Annual Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2025-12-31 | 4.15 |
| 2024-12-31 | 3.24 |
| 2023-12-31 | 3.22 |
| 2022-12-31 | 3.52 |
| 2021-12-31 | 5.10 |
| 2020-12-31 | 4.55 |
| 2019-12-31 | 4.22 |
| 2018-12-31 | 3.51 |
| 2017-12-31 | 3.79 |
| 2016-12-31 | 3.76 |
| 2015-12-31 | 4.65 |
| 2014-12-31 | 4.60 |
| 2013-12-31 | 4.44 |
| 2012-12-31 | 3.31 |
| 2011-12-31 | 3.19 |
| 2010-12-31 | 2.47 |
| 2009-12-31 | 3.06 |
| 2008-12-31 | 3.09 |
| 2007-12-31 | 3.60 |
| 2006-12-31 | 4.41 |
| 2005-12-31 | 4.70 |
| 2004-12-31 | 3.57 |
| 2003-12-31 | 3.36 |
| 2002-12-31 | 1.63 |
| 2001-12-31 | 1.99 |
| 2000-12-31 | 2.84 |
| 1999-12-31 | 3.00 |
| 1998-12-31 | 5.16 |
